Trial uncovers potential dangers of chemotherapy regimen for bladder cancer

the ONA take:

Researchers at Fox Chase Cancer Center were forced to halt a study of a neoadjuvant chemotherapy regimen for muscle-invasive bladder cancer. Although chemotherapy before surgery to remove the tumor is often beneficial, patients in this study experienced serious side effects such as heart attacks and blood clots in the legs and lungs. The recognized standard of care is 12 weeks of gemcitabine and cisplatin. The researchers sought to determine if a 6-week regimen of the same drugs would be more effective and shorten the time to surgery. The researchers reflect that condensing the doses into 6 weeks may have caused problems; however, they note that may not be the only cause of the adverse events, as two of the most severe cardiovascular events occurred after one treatment.

Trial uncovers potential dangers of chemotherapy regimen for bladder cancer
Trial uncovers potential dangers of chemotherapy regimen for bladder cancer
Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs